Since the beginning of neovascular age-related macular degeneration (AMD) therapy, clinicians have been faced with a dilemma—that treatment was most helpful if choroidal neovascularization (CNV) was detected before visual acuity was affected1 but that identifying patients at this early stage was difficult. Self-detection techniques have been less than satisfactory. For instance, Zaidi et al2 described only a 30% detection rate on a self-detection protocol that included the use of the Amsler grid. Poor results have been attributed to difficulty adhering to a regimen of daily use of the Amsler grid and to the insensitivity of the test in detecting change.3,4 Self-detection methods that register, quantify, and compare macular dysfunction over time have not been available. Ideally, an instrument that would integrate these features could be developed. The Home Monitoring of the Eye (HOME) study is a culmination of such an effort.5
Han DP. The ForeSeeHome Device and the HOME Study: A Milestone in the Self-detection of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2014;132(10):1167–1168. doi:10.1001/jamaophthalmol.2014.1405
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.